

# Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/DD38E039C34EN.html>

Date: June 2018

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: DD38E039C34EN

## Abstracts

Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Depomed Inc (Depomed) is a specialty pharmaceutical company that develops and commercializes drugs indicated for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprise products for treatment of indications including postherpetic neuralgia caused due to viral infection, herpes zoster, or nerve damage; management of mild to moderate acute pain in adults; migraine attacks in adults of 18 years of age or above; and pain in cancer patients of 18 years of age and older. The company sells its products to wholesale distributors and retail pharmacies. Depomed also licenses Acuform, its proprietary gastroretentive drug delivery technology. Depomed is headquartered in Newark, California, the US.

### Depomed Inc Key Recent Developments

Jun 05,2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer

May 10,2018: Depomed Announces First-Quarter 2018 Financial Results

Apr 17,2018: Depomed Named John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

Apr 17,2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications

Apr 02,2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Depomed Inc - Key Facts  
Depomed Inc - Key Employees  
Depomed Inc - Key Employee Biographies  
Depomed Inc - Major Products and Services  
Depomed Inc - History  
Depomed Inc - Company Statement  
Depomed Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Depomed Inc - Business Description  
Product Category: CAMBIA  
Overview  
Performance  
Product Category: Gralise  
Overview  
Performance  
Product Category: Lazanda  
Overview  
Performance  
Product Category: NUCYNTA Products  
Overview  
Performance  
Product Category: Zipsor  
Overview  
Performance  
R&D Overview  
Depomed Inc - Corporate Strategy  
Depomed Inc - SWOT Analysis  
SWOT Analysis - Overview  
Depomed Inc - Strengths  
Depomed Inc - Weaknesses

Depomed Inc - Opportunities  
Depomed Inc - Threats  
Depomed Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Depomed Inc, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

May 10, 2018: Depomed Announces First-Quarter 2018 Financial Results  
Apr 17, 2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications  
Apr 02, 2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer  
Mar 19, 2018: Depomed Announces New Corporate Headquarters  
Nov 07, 2017: Depomed Announces Third Quarter 2017 Financial Results  
Oct 18, 2017: Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer  
Aug 07, 2017: Depomed Announces Second Quarter 2017 Financial Results  
May 09, 2017: Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value  
Apr 25, 2017: Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration  
Feb 21, 2017: Depomed Reports Fourth Quarter and Full Year 2016 Financial Results

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Depomed Inc, Key Facts  
Depomed Inc, Key Employees  
Depomed Inc, Key Employee Biographies  
Depomed Inc, Major Products and Services  
Depomed Inc, History  
Depomed Inc, Subsidiaries  
Depomed Inc, Key Competitors  
Depomed Inc, Ratios based on current share price  
Depomed Inc, Annual Ratios  
Depomed Inc, Annual Ratios (Cont.1)  
Depomed Inc, Annual Ratios (Cont.2)  
Depomed Inc, Interim Ratios  
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Depomed Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

Depomed Inc, Performance Chart (2013 - 2017)

Depomed Inc, Ratio Charts

Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Depomed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

### COMPANIES MENTIONED

Purdue Pharma LP

Pernix Therapeutics Holdings Inc

Insys Therapeutics Inc

Arbor Pharmaceuticals LLC

## I would like to order

Product name: Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/DD38E039C34EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD38E039C34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970